Table 2.
Common susceptibility of various Candida species
| Species | Amphotericin B | Echinocandins a | Fluconazole | Itraconazole | Voriconazole b |
|---|---|---|---|---|---|
| Candida albicans | S | S | S to Rc | S | S |
| Candida glabrata | S | S | S-DD to R | S-DD to R | S to Rd |
| Candida krusei | S | S | R | S-DD to R | S |
| Candida lusitaniae | S to Re | S | S | S | S |
| Candida parapsilosis | S | S to Rf | S | S | S |
| Candida tropicalis | S | S | S | S | S |
Adapted from [1,44,67,74,75]. S, susceptible; S-DD, susceptible dose-dependent; R, resistant. aSusceptibility pattern is similar for all the echinocandins available (anidulafungin, caspofungin and micafungin). bPosaconazole has the same susceptibility pattern as voriconazole but, lacking intravenous formulation, has little place in the treatment of candidemia in the intensive care unit. cResistant in approximately 5%. dCross-resistance to azoles in more than 5%.eResistance uncommon but can develop in initially susceptible species. fHigher minimum inhibitory concentration values and poor activity against C. parapsilosis biofilm.